BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Leads Biolabs Completes Patient Enrollment in World’s First Registrational Trial of Immunotherapy for Advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced the successful completion of patient enrollment in t...

August 15, 2025 | News

Thermo Fisher’s Oncomine Dx Target Test Wins FDA Approval to Identify HER2-Mutant NSCLC Patients for HERNEXEOS®

Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS® (zongertinib tablets), the first and only orally administered target...

August 12, 2025 | News

Codex Genetics and Pacific Edge Partner to Introduce Cxbladder Genomic Urine Tests for Bladder Cancer Diagnosis in Hong Kong

Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, announced an exclusive collaboration with Pacific Edge, the deve...

August 11, 2025 | News

Senhwa Advances CX-5461 into NCI-Sponsored Trial for MYC-Aberrant Lymphoma

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...

August 08, 2025 | News

Fapon Biopharma Enrolls First Patient in China Phase I Trial of Novel Immunotherapy FP008 for Solid Tumors

Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollmen...

August 06, 2025 | News

Alphamab Oncology’s Bispecific ADC JSKN022 Clears IND Review in China

Alphamab Oncology announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug...

August 04, 2025 | News

Leo Cancer Care’s Marie® Secures FDA 510(k) Clearance, Pioneering Upright Particle Therapy in the U.S.

Leo Cancer Care, a leader in upright radiotherapy solutions, announces that its flagship product, Marie®, has received 510(k) clearance from the U.S. F...

July 31, 2025 | News

Bristol Myers Squibb and Bain Capital Launch New Biotech Company with $300M to Advance Autoimmune Therapies

Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for...

July 29, 2025 | News

Akeso Enrols First Patient in Phase III Trial of Ivonescimab for Metastatic Pancreatic Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase II...

July 24, 2025 | News

Senhwa Biosciences’ CX-5461 Selected by U.S. National Cancer Institute for Major Oncology Research Programme

Senhwa Biosciences, Inc., a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, ...

July 17, 2025 | News

SN BioScience’s Anticancer Candidate SNB-101 Selected for Korea’s 2025 National Drug Development Programme

SN BioScience announced that its anticancer candidate SNB-101 has been selected as a clinical-stage project under the 2025 Korea Drug Development Project, ...

July 17, 2025 | News

Akeso Begins Phase III Trial of Ivonescimab for Hard-to-Treat Advanced Colorectal Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phas...

July 16, 2025 | News

Concord Healthcare Delivers China’s First Proton Therapy for Choroidal Malignant Melanoma

Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), whic...

July 15, 2025 | News

Stay Connected